FORM: 500.1.04

Academic Personnel Short Profile / Short CV

Institution:	The Cyprus Institute of Neurology and Genetics (CING)
Surname:	Sargiannidou
Name:	Irene
Rank/Position:	Associate Scientist
Program of Study:	MSc in Molecular Medicine / MSc in Medical Genetics / MSc in Neuroscience / MSc in Biomedical Research / MSc in Biotechnology / PhD in Molecular Medicine / PhD in Medical Genetics / PhD in Neuroscience
Scientific Domain: *	Neuroscience

Academic qualifications (list by highest qualification)

Qualification	Year	Awarding Institution	Department	Thesis title
PhD	2003	Drexel University	Molecular Pathobiology	The Functional Significance of Angiocidin in Breast Carcinoma Progression
BS	1994	Plymouth University	Biology	

Employment history in Academic Institutions/Research Centers – List by the three (3) most recent

Period of employment		Employer	Location	Position
From	To			

2005	today	The Cyprus Institute of Neurology & Genetics	Nicosia, Cyprus	Associate Scientist
2003	2003	Temple University	Philadelphia, USA	Lecturer

Key *refereed* journal papers, monographs, books, conference publications etc. List the five (5) more recent and other five (5) selected –(max total 10)

Ref. Number	Year	Title	Other authors	Journal and Publisher/ Conference	Vol.	Pages
1	2018	Regulatory role of oligodendrocyte gap junctions in inflammatory demyelination	Papaneophytou CP, Georgiou E, Karaiskos C, **Sargiannidou I**, Markoullis K, Freidin MM, Abrams CK, Kleopa KA.	Glia	66(12)	2589-2603
2	2017	Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X.	Kyriakoudi S, **Sargiannidou I**, Kagiava A, Olympiou M, Kleopa KA.	Hum Mol Genet	26(9)	1622-1633
3	2016	Intrathecal gene therapy rescues a model of	Kagiava A, **Sargiannidou I**, Theophilidis G, Karaiskos C, Richter J,	Proc Natl Acad Sci.	113(17)	E2421 - E2429

		demyelinating peripheral neuropathy	Bashiardes S, Schiza N, Nearchou M, Christodoulou C, Scherer SS, Kleopa KA			
4	2015	Differential modulation of the juxtaparanodal complex in Multiple Sclerosis	Kastriti ME, **Sargiannidou I**, Kleopa KA, Karagogeos D.	Mol Cell Neurosci	67	93-103
5	2015	Intraneural GJB1 gene delivery improves nerve pathology in a model of CMT1X	**Sargiannidou I**, Kagiava A, Bashiardes S, Richter J, Christodoulou C, Scherer SS, Kleopa KA	Ann Neurol.	78	303-316
6	2015	A start codon CMT1X mutation associated with transient encephalomyelitis causes complete loss of Cx32	**Sargiannidou I**, Kim GH, Kyriakoudi S, Eun BL, Kleopa KA	Neurogenetics	16	193-200
7	2015	Transgenic replacement of Cx32 in gap junction deficient oligodendrocytes rescues the phenotype of a hypomyelinating leukodystrophy model	Schiza N., **Sargiannidou I.,** Kagiava A., Karaiskos C., Nearchou M., Kleopa KA	Hum Mol Genet	24	2049-64
8	2014	Oligodendrocyte gap junction loss and disconnection from reactive astrocytes in multiple sclerosis grey matter	Markoullis K, **Sargiannidou I**, Schiza N, Roncaroli F, Reynolds R, Kleopa KA	J Neuropathol Exp Neurol	73(9)	865-79

9	2012	Gap junction pathology in multiple sclerosis lesions and normal appearing white matter	Markoullis K, **Sargiannidou I**, Schiza N, Hadjisavvas A, Roncaroli F, Reynolds R, Kleopa KA.	Acta Neuropathol.	123(6)	873-86
10	2012	Disruption of oligodendrocyte gap junctions in experimental autoimmune encephalomyelitis	Markoullis K, **Sargiannidou I**, Gardner C, Hadjisavvas A, Reynolds R, Kleopa KA.	Glia	60 (7)	1053-66

Exhibitions (where applicable). List the five (5) more recent and other five (5) selected. (max total 10)

Ref. Number	Date	Topic	International / Local	Location*	Role in Exhibition
1	7/2018	A gene therapy approach for treating CMT4C	International	PNS, Baltimore, USA	Poster presentation
2	9/2016	In vitro screening for interactions between virally delivered Cx32 and neuropathy-associated mutants: towards a gene therapy for CMT1X	International	CMT Consortium, Venice, Italy	Poster presentation
3	10/2014	Intraneural gene delivery improves nerve pathology in a mouse model of X-linked CMT	Local	International Multithematic Biomedical Congress, Nicosia, Cyprus	Poster presentation

4	10/2014	A start codon CMT1X mutation associated with transient encephalomyelitis causes complete loss of Cx32 function	Local	Cyprus Society of Human Genetics, Nicosia, Cyprus	Poster presentation
5	7/2013	Efficient lentiviral gene delivery to Schwann cells	International	PNS, Saint-Malo, France	Oral presentation
6	11/2012	Gene therapy for inherited neuropathy	Local	NeuroMediterranean Congress Nicosia, Cyprus	Poster presentation

Research Projects. List the five (5) more recent and other five (5) selected (max total 10)

Ref. Number	Date	Title	Funded by	Project Role*
1	9/2019-8/2021	AAV mediated gene therapy for CMT4C	CMT Association	Research Team Member
2	6/2019-6/2020	Gene therapy for inherited demyelinating neuropathies	Cyprus Seeds	Research Team Member
3	2/2019-1/2022	A translatable gene therapy for CMT1X	Muscular Dystrophy Association	Research Team Member
4	2/2019-1/2021	Developing a gene silencing approach to treat CMT1A	CMT Research Association	Research Team Member
5	10/2018-9/2021	Generation of disease models for inherited neuropathy CMT2A and testing of neuroprotective therapy	Telethon	Research Team Member

6	10/2016-9/2019	Development of gene therapy for CMT2A neuropathy	Balakanakis Bros	Research Team Member
7	8/2013-7/2016	Developing Gene Therapy for inherited Neuropathy	Muscular Dystrophy Association	Research Team Member

Academic Consulting Services and/or Participation in Councils / Boards/ Editorial Committees. List the five (5) more recent (Optional Entry)

Ref. Number	Period	Organization	Title of Position or Service	Key Activities
1	-	-	-	-

Awards / International Recognition (where applicable). List the five (5) more recent and other five (5) selected. (max total 10) (Optional Entry)

Ref. Number	Date	Title	Awarded by:
1	-	-	-

Other Achievements. List the five (5) more recent and other five (5) selected. (max total 10) (Optional Entry)

Ref. Number	Date	Title	Key Activities:
1	-	-	-